ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Plaintiffs’ Attorneys Respond to Bayer’s Threat to Pull Roundup from Market

Bayer, Monsanto aim to protect its revenue “no matter the cost to human life”

Attorneys representing thousands of cancer victims criticized Bayer today for what they describe as an attempt to pressure courts, lawmakers and the public by threatening to pull its popular Roundup weedkiller from the market amid ongoing litigation.

Video of the plaintiffs’ attorneys’ reactions is available here.

Speaking at Bayer’s annual shareholders meeting, CEO Bill Anderson warned that continued lawsuits could make it financially unsustainable for the company to continue selling Roundup. The plaintiffs’ attorneys say the company’s remarks are not an acceptance of responsibility, but a calculated threat aimed at protecting Bayer’s financial interests at the expense of public health and accountability.

“Bayer’s CEO is using the threat of pulling Roundup as a blackmail attempt, pressuring legislators and the public to protect Bayer’s profits rather than holding the company accountable for the injuries it has caused,” said Nachawati Law Group partner Erin Wood, whose Dallas-based firm represents more than 5,000 cancer victims against the manufacturers. “This is a multibillion-dollar corporation doing everything it can to protect its revenue, no matter the cost to human life.”

The lawyers say Bayer’s multi-pronged strategy includes:

  • Pushing for federal preemption: earlier this month, Monsanto filed a petition asking the U.S. Supreme Court to rule that federal pesticide regulations preempt state law failure-to-warn claims, which would severely limit victims' ability to sue for injuries caused by Roundup.
  • State-level immunity legislation: Bayer and Monsanto are supporting bills in several states that would give pesticide companies immunity from lawsuits. These bills would block individuals harmed by pesticides, including cancer victims, from seeking compensation.
  • Selective settlements: even as Bayer warns publicly about the financial pressure of litigation, it continues to settle some cases while pursuing strategies to limit its overall liability.

According to trial evidence, Monsanto has long downplayed known cancer risks associated with exposure to glyphosate, the main ingredient in Roundup, while working behind the scenes to influence scientific research and avoid adding warning labels.

“The safety of American citizens is not for sale,” said firm founder Majed Nachawati. “Although we are aware of Bayer and Monsanto’s efforts to influence legislation to shield them from accountability, our firm will continue to fight tooth and nail in the legislature and in court to protect the legal rights of every citizen.”

Mr. Nachawati and his team have been a leading voice in opposing Monsanto’s efforts to sidestep accountability for thousands of cancer claims tied to Roundup.

To date, Bayer has reportedly spent more than $10 billion to settle thousands of cancer claims. Despite repeated efforts to limit its liability, the company continues to face ongoing litigation, has secured shareholder approval for a potential capital raise to cover legal costs and has made a third request for intervention by the U.S. Supreme Court.

About Nachawati Law Group

Nachawati Law Group represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation and individual victims in complex personal injury litigation. For more information, visit https://ntrial.com

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.